Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573228 | 0.83 | ADRB2 (0.48) | ADRB2ADRB1SMN1; SMN2KMT2AGAA | |
| SCHEMBL3585196 | 0.80 | SMN1; SMN2 (0.44) | ADRB2ADRB1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL3580418 | 0.78 | MEN1 (0.48) | ADRB2ADRB1SMN1; SMN2KMT2A | |
| SCHEMBL14157447 | 0.78 | ADRB2 (0.54) | ADRB2ADRB1SMN1; SMN2KMT2AGAA | |
| SCHEMBL30416351 | 0.75 | ADRB2 (0.65) | ADRB2ADRB1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL1496566 | 0.75 | ADRB2 (0.65) | ADRB2ADRB1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL16095797 | 0.75 | ADRB2 (0.50) | ADRB2ADRB1SMN1; SMN2KMT2AGAA | |
| SCHEMBL16095798 | 0.75 | ADRB2 (0.50) | ADRB2ADRB1SMN1; SMN2KMT2AGAA | |
| SCHEMBL28430912 | 0.75 | ADRB2 (0.50) | ADRB2ADRB1SMN1; SMN2KMT2AGAA | |
| SCHEMBL29996159 | 0.75 | ADRB2 (0.50) | ADRB2ADRB1SMN1; SMN2KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728005-B2 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060270693-A1 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1679296-A1 | ETHER DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270693-A1 | Ether derivative | UROD, IL5, IL17A | ADRB2 405/4885ADRB1 493/4885SMN1; SMN2 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.